Literature DB >> 7760871

New neuromuscular blocking drugs.

J M Hunter1.   

Abstract

The new nondepolarizing neuromuscular blocking drugs have specific advantages over succinylcholine. Rocuronium has an onset of action that is almost as rapid as that of succinylcholine and may be useful in patients with residual gastric contents. This drug may replace vecuronium, since the two agents are otherwise similar. The onset of action of mivacurium is similar to that of atracurium, but recovery from the blockade is more rapid (if the plasma cholinesterase level is normal), making mivacurium useful for short procedures. Although pipecuronium and doxacurium have minimal effects on the cardiovascular system, their long and variable onset and duration of action limit their usefulness. The need for either drug is questionable. There is still a need, however, for a nondepolarizing drug that has an onset of action as rapid as that of succinylcholine but a duration of action similar to that of mivacurium, with no adverse cardiovascular effects and clearance from the body that is independent of organ function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7760871     DOI: 10.1056/NEJM199506223322507

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  19 in total

Review 1.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  General anaesthesia in elderly patients with cardiovascular disorders: choice of anaesthetic agent.

Authors:  Sangeeta Das; Kirsty Forrest; Simon Howell
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 3.  [New muscle relaxants. Update on mivacurium, rocuronium and cis-atracurium].

Authors:  T Fuchs-Buder
Journal:  Anaesthesist       Date:  1997-04       Impact factor: 1.041

4.  Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome.

Authors:  Marc Moss; David T Huang; Roy G Brower; Niall D Ferguson; Adit A Ginde; M N Gong; Colin K Grissom; Stephanie Gundel; Douglas Hayden; R Duncan Hite; Peter C Hou; Catherine L Hough; Theodore J Iwashyna; Akram Khan; Kathleen D Liu; Daniel Talmor; B Taylor Thompson; Christine A Ulysse; Donald M Yealy; Derek C Angus
Journal:  N Engl J Med       Date:  2019-05-19       Impact factor: 91.245

Review 5.  Neurologic Complications of Commonly Used Drugs in the Hospital Setting.

Authors:  Elliot T Dawson; Sara E Hocker
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 6.  Sedation and neuromuscular blocking agents in acute respiratory distress syndrome.

Authors:  Jeremy Bourenne; Sami Hraiech; Antoine Roch; Marc Gainnier; Laurent Papazian; Jean-Marie Forel
Journal:  Ann Transl Med       Date:  2017-07

7.  Reversal of rocuronium-induced neuromuscular block by sugammadex is independent of renal perfusion in anesthetized cats.

Authors:  Lonneke M Staals; Hans D de Boer; Jan van Egmond; Frank Hope; Francien van de Pol; Anton H Bom; Jacques J Driessen; Leo H D J Booij
Journal:  J Anesth       Date:  2011-01-12       Impact factor: 2.078

Review 8.  Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment.

Authors:  D Chambers; M Paulden; F Paton; M Heirs; S Duffy; J M Hunter; M Sculpher; N Woolacott
Journal:  Br J Anaesth       Date:  2010-10-11       Impact factor: 9.166

Review 9.  Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

Authors:  H M Bryson; D Faulds
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

10.  A fresh look at paralytics in the critically ill: real promise and real concern.

Authors:  David Price; Nicholas J Kenyon; Nicholas Stollenwerk
Journal:  Ann Intensive Care       Date:  2012-10-12       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.